{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:10:59Z","timestamp":1791486659390,"version":"4.3.4"},"reference-count":0,"publisher":"ScopeMed","issue":"1","license":[{"start":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T00:00:00Z","timestamp":1710028800000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/www.matersociomed.org\/?sec=licenseinfo"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mater Sociomed"],"published-print":{"date-parts":[[2024]]},"abstract":"<jats:p>Background: Primary central nervous system lymphoma(PCNSL) is an aggressive, rare form of Non-Hodgkin lymphoma, characterized by the absence of systemic disease. There are limited data and no strictly defined guidelines for management of PCNSL. Objective: The aim of this study was to report a 10 year experience of PCNSL treatment, to evaluate treatment outcomes and asses Progression Free and Overall Survival of these patients. Methods: Study was conducted on the Haematology Clinic, Clinical center University of Sarajevo, BH, in the period from January 2012.-December 2022. Total sample of 24 patients were enrolled. All have undergone diagnostic surgery. Patients were treated with regimens based on High dose Methotrexate, with\/without whole brain radiotherapy as consolidation. Treatment response was captured by imaging techniques. Patients who have relapsed were evaluated with imaging techniques and treated according to Methotrexate-based treatment protocols. Results: We have captured equal gender distribution. The median age of patients was 59.5 years (range 20-79). Pathohistological analysis confirmed DLBCL diagnosis in 22 patients, T cell lymphoma and anaplastic large cell lymphoma, each in 1 patient. Chemotherapy, chemotherapy combined with WBRT and radiotherapy were given to 5, 18 and 1 patients, respectively. The overall complete response rate (CR) was 87,15%. \u00a0Those receiving combined modality-treatment had higher CR than those receiving chemotherapy (94,4% versus 60%). Out of 24 patients, 11 of them relapsed. The median time to relapse was 29 months (from 1 to 105). After second line of the treatment, CR was 54,5%, while 45,45% of patients died during the treatment. 4 patients relapsed for the second time with median time to relapse of 9 months (from 2 to 77). 2 year OS rate was 67%, and the median OS rate was 45,9 months.\u00a02 year PFS rate was 31%. Conclusion: The OS and PFS rates indicate the usage of new drugs and consolidation with autologous stem cell transplantation in patients with PCNSL in order to achieve better treatment outcomes.<\/jats:p>","DOI":"10.5455\/msm.2024.36.23-25","type":"journal-article","created":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T17:55:51Z","timestamp":1710093351000},"page":"23","source":"Crossref","is-referenced-by-count":0,"title":["Primary Central Nervous System Lymphoma, Treatment Outcomes - 10 Year Experience. Single Center Study"],"prefix":"10.5455","volume":"36","author":[{"given":"Ajla","family":"Nizic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lejla","family":"Balic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timur","family":"Ceric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Omerhodzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lejla","family":"Burazerovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasvija","family":"Saric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emina","family":"Mameledzija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berina","family":"Hasanefendic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3407","container-title":["Materia Socio Medica"],"original-title":[],"link":[{"URL":"https:\/\/ejmanager.com\/mnstemps\/16\/16-1710076410.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:08:23Z","timestamp":1791482903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejmanager.com\/mnstemps\/16\/16-1710076410.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5455\/msm.2024.36.23-25","relation":{},"ISSN":["1512-7680"],"issn-type":[{"value":"1512-7680","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}